| Literature DB >> 35351656 |
Zhengxin Chen1, Shuai Wang2, Hai-Lin Li3, Hui Luo3, Xiaoting Wu4, Jiacheng Lu3, Hong-Wei Wang5, Yuanyuan Chen6, Dan Chen7, Wen-Ting Wu8, Shuyu Zhang9, Qiongqiong He10, Daru Lu11, Ning Liu3, Yongping You1, Wei Wu12, Huibo Wang13.
Abstract
Proneural (PN) to mesenchymal (MES) transition (PMT) is a crucial phenotypic shift in glioblastoma stem cells (GSCs). However, the mechanisms driving this process remain poorly understood. Here, we report that Fos-like antigen 1 (FOSL1), a component of AP1 transcription factor complexes, is a key player in regulating PMT. FOSL1 is predominantly expressed in the MES subtype, but not PN subtype, of GSCs. Knocking down FOSL1 expression in MES GSCs leads to the loss of MES features and tumor-initiating ability, whereas ectopic expression of FOSL1 in PN GSCs is able to induce PMT and maintain MES features. Moreover, FOSL1 facilitates ionizing radiation (IR)-induced PMT and radioresistance of PN GSCs. Inhibition of FOSL1 enhances the anti-tumor effects of IR by preventing IR-induced PMT. Mechanistically, we find that FOSL1 promotes UBC9-dependent CYLD SUMOylation, thereby inducing K63-linked polyubiquitination of major nuclear factor κB (NF-κB) intermediaries and subsequent NF-κB activation, which results in PMT induction in GSCs. Our study underscores the importance of FOSL1 in the regulation of PMT and suggests that therapeutic targeting of FOSL1 holds promise to attenuate molecular subtype switching in patients with glioblastomas.Entities:
Keywords: FOSL1; UBC9/CYLD/NF-κB axis; glioblastoma stem cells; proneural-to-mesenchymal transition
Mesh:
Substances:
Year: 2022 PMID: 35351656 PMCID: PMC9263249 DOI: 10.1016/j.ymthe.2021.10.028
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 12.910